Table 2.
Hazard ratios (HRs) for end-stage renal disease (ESRD) and overall mortality in three cohorts.
| Outcome | Crude | Adjusted | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
| ESRD * | ||||||
| Control (n = 4361) | 1.00 | Reference | 1.00 | Reference | ||
| PPI cohort (n = 4361) | 2.02 | 1.65–2.48 | <0.0001 | 1.15 | 0.91–1.45 | 0.24 |
| H2RA cohort (n = 4361) | 0.57 | 0.43–0.75 | <0.0001 | 0.40 | 0.30–0.53 | <0.0001 |
| Overall mortality # | ||||||
| Control (n = 4361) | 1.00 | Reference | 1.00 | Reference | ||
| PPI cohort (n = 4361) | 2.54 | 2.31–2.80 | <0.0001 | 1.83 | 1.65–2.03 | <0.0001 |
| H2RA cohort (n = 4361) | 0.98 | 0.88–1.09 | 0.70 | 0.64 | 0.57–0.72 | <0.0001 |
Abbreviations: CI, confidence interval; others same as Table 1. * Adjusted for all covariates (age per year, sex, comorbidities, number of medical visits, NSAID, and ACEI/ARB) and competing mortality. # Adjusted for all covariates (age per year, sex, comorbidities, number of medical visits, NSAID, and ACEI/ARB).